GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivoryon Therapeutics NV (FRA:05Y) » Definitions » Capital Expenditure

Vivoryon Therapeutics NV (FRA:05Y) Capital Expenditure : €-0.51 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Vivoryon Therapeutics NV Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Vivoryon Therapeutics NV's cash flow for capital expenditures for the six months ended in Dec. 2023 was €-0.51 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.51 Mil.

Vivoryon Therapeutics NV Capital Expenditure Historical Data

The historical data trend for Vivoryon Therapeutics NV's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivoryon Therapeutics NV Capital Expenditure Chart

Vivoryon Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.64 -0.03 -0.01 -0.51

Vivoryon Therapeutics NV Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.01 -0.01 -0.51

Vivoryon Therapeutics NV Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV (FRA:05Y) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivoryon Therapeutics NV (FRA:05Y) » Definitions » Capital Expenditure
Comparable Companies
XAMS:BAI XAMS:PHARM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270 BMRN XBRU:UCB RPRX
Traded in Other Exchanges
VVY:Netherlands
Address
Weinbergweg 22, Halle, SN, DEU, 06120
Website
https://www.vivoryon.com
Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products include PQ912 and PQ1565. Geographically, the majority is from Greater China.

Vivoryon Therapeutics NV (FRA:05Y) Headlines

No Headlines